Filing Flows › Bristol Myers Squibb (BMY) › Q3 2026 › vs Q2 2026
Bristol Myers Squibb (BMY) Q3 2026 vs Q2 2026 (quarter over quarter)
Bristol Myers Squibb's revenue rose $96.0M (+0.7%) from $13.0B in Q2 2026 to $13.1B in Q3 2026. Operating margin 19.4% against 31.5% (-12.1 pts).
Bristol Myers Squibb, Q3 2026: revenue $13.1B (+7% year over year), operating margin 19.4%, net earnings $2.2B, operating cash flow $4.2B. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Operating margin | 19.4% | 31.5% | -12.1 pts |
| Net margin | 16.5% | 25.6% | -9.0 pts |
| Free cash flow margin | 29.4% | 23.8% | +5.6 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Revenue | $13.1B | $13.0B | $96.0M | +0.7% |
| Operating profit | $2.5B | $4.1B | −$1.6B | -38% |
| Costs & expenses | $10.5B | $8.9B | $1.6B | +19% |
| Pre-tax earnings | $2.5B | $4.1B | −$1.6B | -38% |
| Cost of revenue | $4.1B | $3.7B | $420M | +11% |
| Research & development | $2.4B | $3.0B | −$594M | -20% |
| SG&A | $1.7B | $1.8B | −$127M | -7% |
| Other operating costs | $2.3B | $376M | $1.9B | +518% |
| Net earnings | $2.2B | $3.3B | −$1.2B | -35% |
| Income tax | $374M | $770M | −$396M | -51% |
| Depreciation & amortization | $626M | $594M | $32.0M | +5% |
| Share-based compensation | $138M | $135M | $3.0M | +2% |
| Working capital & other | $1.3B | −$652M | $1.9B | — |
| Operating cash flow | $4.2B | $3.4B | $788M | +23% |
| Free cash flow (OCF − capex) | $3.8B | $3.1B | $749M | +24% |
| Capital expenditures | $344M | $305M | $39.0M | +13% |
Questions
How much did Bristol Myers Squibb's revenue grow quarter over quarter in Q3 2026?
Bristol Myers Squibb's revenue rose $96.0M (+0.7%) from $13.0B in Q2 2026 to $13.1B in Q3 2026. Operating margin 19.4% against 31.5% (-12.1 pts).